Triphenylselenonium and diphenylselenide in cancer chemoprevention: Comparative studies of anticarcinogenic efficacy, tissue selenium levels and excretion profile

Anticancer Research

Volumn 17, Issue 5 A, 1997, Pages 3195-3199

  Ip, Clement ^a   Lisk, Donald J ^a   Ganther, Howard ^b   Thompson, Henry J ^c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Cancer chemoprevention; Diphenylselenide; Tissue selenium; Triphenylselenonium; Urinary and fecal analysis

Indexed keywords

ORGANOSELENIUM DERIVATIVE; SELENIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; DRUG ACCUMULATION; DRUG EFFICACY; DRUG EXCRETION; FECES; FEMALE; KIDNEY; LIVER; MAMMARY GLAND; NONHUMAN; ORAL DRUG ADMINISTRATION; PLASMA; PRIORITY JOURNAL; RAT;

ANIMALS; CHEMOPREVENTION; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; ORGANOSELENIUM COMPOUNDS; RATS; RATS, SPRAGUE-DAWLEY; SELENIUM;

EID: 0030815274     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Ip C, Thompson H and Ganther H: Activity of triphenylselenonium chloride in mammary cancer prevention. Carcinogenesis 15: 2879-2882, 1994.
2. Ip C and Ganther HE: Activity of methylated forms of selenium in cancer prevention. Cancer Res 50: 1206-1211, 1990.
3. Ip C, Hayes C, Budnick RM and Ganther HE: Chemical form of selenium, critical metabolites, and cancer prevention. Cancer Res 51: 595-600, 1991.
4. Nayini J, El-Bayoumy K, Sugie S, Cohen LA and Reddy BS: Chemoprevention of experimental mammary carcinogenesis by the synthetic organoselenium compound, benzylselenocyanate, in rats. Carcinogenesis 10: 509-512, 1989.
5. El-Bayoumy K, Chae Y-H, Upadhyaya P, Meschter C, Cohen LA and Reddy BS: Inhibition of 7,12-dimethylbenz(a)anthracene-induced tumors and DNA adduct formation in the mammary glands of female Sprague-Dawley rats by the synthetic organoselenium compound, 1,4-phenylenebis(methylene)selenocyanate. Cancer Res 52: 2402-2407, 1992.
6. Cummins LM and Kimura ET: Safety evaluation of selenium sulfide antidandruff shampoos. Toxicol Appl Pharmacol 20: 89-96, 1971.
7. Schwarz K and Foltz CM: Factor 3 activity of selenium compounds. J Biol Chem 233: 245-251, 1958.
8. Lien EJ: Structure-absorption-distribution relationships: Significance for drug design. In: Medicinal Chemistry, Vol. V (Ed. Ariens EJ), pp. 81-132. Academic Press, New York, 1975.
9. Ip C, El-Bayoumy K, Upadhyaya P, Ganther H, Vadhanavikit S and Thompson H: Comparative effect of inorganic and organic selenocyanate derivatives in mammary cancer chemoprevention. Carcinogenesis 15: 187-192, 1994.
10. Report of the American Institute of Nutrition Ad Hoc Committee on Standards for Nutritional Studies: J Nutr 107: 1340-1348, 1977.
11. Horvath PM and Ip C: Synergistic effect of vitamin E and selenium in chemoprevention of mammary carcinogenesis in rats. Cancer Res 43: 5335-5341, 1983.
12. Olson OE, Palmer IS and Cary EE: Modification of the official fluorometric method for selenium in plants. J Assoc Offic Anal Chem 58: 117-121, 1975.
13. Shine RJ: Selenonium compounds. In: Organic Selenium Compounds: Their Chemistry and Biology (Eds. Klayman DK and Gunther WHH), pp. 223-243. Wiley-Interscience, New York, 1973.
14. Lu J, Cheng J, Kaeck M, Ganther H, Ip C and Thompson H: Cellular and metabolic effects of triphenylselenonium chloride in a mammary cell culture model. Carcinogenesis 16: 513-517, 1995.
15. Barrett RH and Selwyn MJ: Effects of triphenylsulfonium ions on mitochondria. Biochem J 156: 315-322, 1976.
16. Bowman BJ, Mainzer SE, Allen KE and Slayman CW: Effects of inhibitors on the plasma membrane and mitochondrial adenosine triphosphatases of Neurospora crassa. Biochim Biophys Acta 512: 13-28, 1978.
17. Ip C and Ganther H: Relationship between chemical form of selenium and anticarcinogenic activity. In: Cancer Chemoprevention (Eds. Wattenberg L, Lipkin M, Boone CW and Kelloff GJ), pp. 479-488. CRC Press, Boca Raton, FL, 1992.
18. Goeger DE and Ganther HE: Oxidation of dimethylselenide to dimethylselenoxide by microsomes from rat liver and lung and by flavin-containing monooxygenase from pig liver. Arch Biochem Biophys 310: 448-451, 1994.
19. Chen G-P and Ziegler DM: Liver microsome and flavin-containing monooxygenase catalyzed oxidation of organic selenium compounds. Arch Biochem Biophys 312: 566-572, 1994.
20. Adams WJ, Kocsis JJ and Snyder R: Acute toxicity and urinary excretion of diphenyldiselenide. Toxicol Lett 48: 301-310, 1989.
21. Reddy BS, Rivenson A, Kulkarni N, Upadhyaya P and El-Bayoumy K: Chemoprevention of colon carcinogenesis by the synthetic organoselenium compound 1,4-phenylenebis(methylene) selenocyanate. Cancer Res 52: 5635-5640, 1992.
22. El-Bayoumy K, Upadhyaya P, Desai DH, Amin S and Hecht SS: Inhibition of 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone tumorigenicity in mouse lung by the synthetic organoselenium compound, 1-4-phenylenebis(methylene)selenocyanate. Carcinogenesis 14: 1111-1113, 1993.
23. Sohn OS, Li H, Surace A, El-Bayoumy K, Upadhyaya P and Fiala ES: Contrasting patterns of selenium excretion by female CD rats treated with chemically related chemopreventive organic selenocyanate compounds. Anticancer Res 15: 1849-1856, 1995.
24. Biegon A, Brewster M, Degani H, Pop E, Somjen D and Kaye AM: A permanently charged Tamoxifen derivative displays anticancer activity and improved tissue selectivity in rodents. Cancer Res 56: 4328-4331, 1996.